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background: High on-treatment platelet reactivity (HPR) is a predictor of major adverse cardiac events (MACE) after percutaneous coronary 
intervention (PCI), as is the presence of chronic kidney disease. There is a paucity of clinical data in high-risk patients on hemodialysis (HD), and 
whether HPR impacts outcomes among HD patients is unknown.
Methods: One-year outcomes of patients from the prospective, multicenter ADAPT-DES study (n=8582) were assessed according to HD status. All 
patients underwent platelet function testing with the VerifyNow assay; HPR was defined as platelet reactivity units (PRU) >208.
results: HD patients (n=138) were more likely to be African American (15.2% vs. 5.2%), diabetic, and hypertensive, and had more frequent prior 
revascularization procedures. The clinical presentation, extent of coronary artery disease and the number of stents placed were comparable between 
HD and non-HD patients. HD patients had significantly higher baseline PRU (mean 218 vs. 187, p<0.001); among HD patients, the incidence of 
HPR was 53.4%, compared to 42.6% among non-HD patients (p=0.012). HPR among HD patients was associated with a trend for an increased 
1-year rate of MACE (15.6% vs. 6.5%, p=0.12), largely driven by a higher incidence of myocardial infarction and clinically driven target lesion 
revascularization. In unadjusted analyses, HD was strongly associated with 1-year death, myocardial infarction, stent thrombosis, and MACE. However, 
after adjustment for HPR and other covariates in propensity-adjusted models, HD (compared with no HD) was less strongly associated with adverse 
clinical events at 1 year, with significance achieved only for stent thrombosis (HR 2.89 [1.08, 7.75], p=0.034), but not for myocardial infarction, 
overall mortality, or MACE.
conclusions: More than half of HD patients exhibit HPR after PCI, and HD was strongly associated with 1-year adverse outcomes following PCI. The 
independent association of HD with ischemic outcomes appears to be at least partially mediated by HPR and other confounders.
